Recently, it was shown that the deletion of CCR2 in breast cancer cells leads to a reduction of tumor growth through changes in the TME, including increased infiltration and activation of CD8+ T cells and cross-presenting CD103+ DCs, and the upregulation of MHCI expression (49). This evidence concerns the gene CD8A and breast carcinoma.